Jian Zhu

This study uses CRISPR-Cas13X to target HIV-1 TAR RNA, inhibiting viral reactivation and reducing viral load in infected cells.

This study shows that inhibiting KDM5A/B enhances antitumor innate immune responses and induces KSHV lytic reactivation in KSHV-positive B-cell lymphomas.

This study shows that levosimendan inhibits HIV-1 infection in myeloid cells through RIOK1-dependent mechanisms.

The paper identifies PRDM6 as a promoter of tumor progression in HNSCC by modulating immune gene expression using scRNA-seq data and IRIS3 analysis.